| Trial ID: | L4531 |
| Source ID: | NCT05408936
|
| Associated Drug: |
Sglt2 Inhibitor
|
| Title: |
SGLT2 Inhibitors and Effects on Hematopoiesis, Inflammation and Metabolic Markers
|
| Acronym: |
SGLT2HgB
|
| Status: |
ACTIVE_NOT_RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: SGLT2 inhibitor
|
| Outcome Measures: |
Primary: Hemoglobin, 0-1-3 months|Erythropoetin, 0-1-3 months|NT-proBNP, 0-1-3 months |
|
| Sponsor/Collaborators: |
Sponsor: University of Patras
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
80
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2022-06-03
|
| Completion Date: |
2024-06-01
|
| Results First Posted: |
|
| Last Update Posted: |
2024-05-14
|
| Locations: |
University Hospital of Patras, Patras, 26504, Greece
|
| URL: |
https://clinicaltrials.gov/show/NCT05408936
|
